首都医科大学学报 ›› 2008, Vol. 29 ›› Issue (2): 205-208.

• 临床研究 • 上一篇    下一篇

ApoA Ñ-75 bp位点基因多态性与普伐他汀调脂效果的相关性

纪璟峰1, 赵秀丽1, 武峰1, 王淑民1, 李嘉静1, 周辉1, 杨凌2, 尚军2   

  1. 1. 首都医科大学附属北京同仁医院临床药理基地;2. 首都医科大学附属北京同仁医院中心实验室
  • 收稿日期:2007-08-31 修回日期:1900-01-01 出版日期:2008-04-24 发布日期:2008-04-24
  • 通讯作者: 赵秀丽

Correlation between -75 bp Polymorphisms of ApoA Ñ Gene and the Lipid Regulatory Effect of Pravastatin in Patients with Hyperlipidemia

Ji Jingfeng1, Zhao Xiuli1, Wu Feng1, Wang Shumin1, Li Jiajing1, Zhou Hui1, Yang Ling2, Shang Jun2   

  1. 1. Base for Drug Clinical Trial, Beijing Tongren Hospital, Capital Medical University;2. Central Laboratory, Beijing Tongren Hospital, Capital Medical University
  • Received:2007-08-31 Revised:1900-01-01 Online:2008-04-24 Published:2008-04-24

摘要: 目的 探讨载脂蛋白A Ñ(apoA Ñ)基因-75 bp位点多态性与普伐他汀调脂效果的相关性.方法 将83例患者分为口服普伐他汀组(45例)和对照组[38例,口服多廿烷醇(又名普利醇)组],于治疗后12周检测血脂水平.采用多聚酶链式反应限制性内切酶片段长度多态性方法(PCR-RFLP)分析患者apoA Ñ基因的 75 bp位点基因型.结果 载脂蛋白A Ñ(apoA Ñ)基因-75 bp位点A/A+G/A基因型服用普伐他汀12周后总胆固醇(TC)降低(P=0.001),差异有统计学意义,而G/G基因型对TC的降低不明显(P=0.083),服用普利醇组的A/A+G/A基因型TC降低的亦不明显(P=0.257),G/G基因型服用普利醇TC降低(P=0.004),差异有统计学意义.结论 apoA Ñ基因-75 bp位点A/A+G/A基因型与G/G基因型影响高脂血症患者服用普伐他汀降低TC的反应性.

关键词: 载脂蛋白A Ñ, 血脂, Msp Ñ, 普伐他汀, 普利醇, 基因多态性, 总胆固醇

Abstract: Objective To investigate the relationship between apolipoprotein A Ñ(apoA Ñ) gene polymorphism and effects of pravastatin and policosan on regulation of lipid metabolism in hypercholesterolemic individuals. Methods Eighty-three patients with hyperlipidemia were enrolled in and treated with policosan or pravastatin for 12 weeks. The restriction fragment length polymorphisms(RFLPS) ploymorphic sites of MspI was used to detect the -75 bp polymorphisms of apoA Ñ gene in these patients. For all subjects the serum lipids profiles were measured. Results After 12-weeks'treatment with pravastatin, the decrease of triglyceride(TG) with A/A+G/A genotype patients was from (6.66±0.98)mmol/L to (6.07±1.02)mmol/L(P=0.001), while the decrease of TC with G/G genotype patients was from (6.55±0.75)mmol/L to (6.16±0.75)mmol/L(P=0.083); however, After 12-weeks'treatment with policosan, the decrease of TG with A/A+G/A genotype patients was from(6.54±0.54)mmol/L to (6.34±1.29)mmol/L(P=0.257), while the decrease of TC with G/G genotype was from (6.60±0.76)mmol/L to (6.12±0.71)mmol/L(P=0.004). Conclusion ApoA-Ñ polymorphisms are correlated with variations in serum triglyceride concentrations in hypercholesterolemic individuals. Our results suggest that the A/A+G/A polymorphism of the apoA-Ñ promoter region is correlated with the decrease of serum cholesterol level in response to pravastatin treatment and the G/G polymorphism is correlated with decrease of serum cholesterol in response to policosan treatment.

Key words: apolipoprotein A-Ñ, lipids, Msp Ñ, pravastatin, policosan, gene polymorphism, triglyceride

中图分类号: